Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $14.2552W HIGH $48.51
Volume
25.32 K
Value Traded
89.24 M
Short % Float
11.65%
-5.24%Week
-9.59%1 Month
-13.61%3 Month
+19.53%6 Month
+16.33%5 Year
+21.11%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.29 B
EPS (TTM)
-1.82
P/E Ratio
-
Ent. Value
3.80 B
Total Shares
108.60 M
Float Shares
81.92 M
Insiders
24.57%
Institutions
86.75%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
EWTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Edgewise Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Edgewise Therapeutics, Inc.
201Total events
9Upcoming
52Tier-1 (high impact)
2020 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedEDG-15400Trial
First patient dosed in Phase 2 EQUINOX-HFpEF trial of EDG-15400
symptomatic heart failure with preserved ejection fraction (HFpEF)source ↗
▲Preclinical PoCEDG-7500Preclinical
Preclinical data supporting EDG-7500 RLC-targeting MoA announced
hypertrophic cardiomyopathysource ↗
●PublicationEDG-7500Presentation
Peer-reviewed publication describing EDG-7500 MoA to be released
hypertrophic cardiomyopathysource ↗
▲Topline ReadoutEDG-7500Clinical Data
Positive top-line data from 12-week Phase 2 CIRRUS-HCM trial
hypertrophic cardiomyopathysource ↗
▲AcquiredCorporate
Servier completes acquisition of Edgewise Therapeutics' muscular dystrophy business
Becker muscular dystrophy, Duchenne muscular dystrophysource ↗
▲AcquisitionSevasemtenFiledCorporate
Servier acquires sevasemten and muscular dystrophy business from Edgewise
Becker and Duchenne muscular dystrophysource ↗
▲Topline ReadoutEDG-7500Clinical Data
Positive 12-week data from Part D of CIRRUS-HCM Phase 2 trial
hypertrophic cardiomyopathy (oHCM and nHCM)source ↗
▲Enrollment CompleteSevasemtenFiledTrial
GRAND CANYON pivotal cohort fully enrolled with 175 participants
Becker muscular dystrophysource ↗
▲AcquisitionSevasemtenFiledCorporate
Completed sale of sevasemten and muscular dystrophy business to Servier
muscular dystrophysource ↗
▲Topline ReadoutEDG-7500Clinical Data
Positive top-line results from 12-week Phase 2 Part D CIRRUS-HCM trial
obstructive and nonobstructive hypertrophic cardiomyopathysource ↗
●Oral PresentationEDG-7500Presentation
Webcast to discuss top-line data with management and cardiology experts
obstructive and nonobstructive hypertrophic cardiomyopathysource ↗
▲Partnership / LicenseSevasemtenFiledCorporate
Edgewise enters definitive agreement to sell sevasemten and muscular dystrophy business to Servier for up to $2.65B
Becker and Duchenne muscular dystrophysource ↗
▲Enrollment CompleteSevasemtenFiledTrial
GRAND CANYON pivotal cohort fully enrolled with 175 participants
Becker muscular dystrophysource ↗
▲AcquiredSevasemtenFiledCorporate
Edgewise acquired by Servier for sevasemten and muscular dystrophy business
Becker and Duchenne muscular dystrophysource ↗
●Quarterly UpdateCorporate
Reaffirmed plan to report 12-week CIRRUS-HCM Part D data in Q2 2026
▲Topline ReadoutEDG-7500Clinical Data
Positive top-line data from 12-week Phase 2 CIRRUS-HCM trial of EDG-7500
hypertrophic cardiomyopathysource ↗
◆Oral PresentationPresentation
Edgewise Therapeutics to present at RBC Capital Markets Global Healthcare Conference
▲Long Term DataSevasemtenFiledClinical Data
Positive long-term sevasemten data demonstrating sustained functional stabilization up to 3.5 years in Becker
Becker muscular dystrophysource ↗
▲Poster PresentationSevasemtenFiledPresentation
Poster presentation of CANYON study cardiac profile analysis
Becker muscular dystrophysource ↗
▲Oral PresentationSevasemtenFiledPresentation
Positive long-term sevasemten data from MESA OLE presented at MDA Clinical and Scientific Conference
Becker muscular dystrophysource ↗
◆Topline ReadoutEDG-7500Clinical Data
12-week Part D data from CIRRUS-HCM Phase 2 trial of EDG-7500 expected
hypertrophic cardiomyopathy (oHCM and nHCM)source ↗
◆Oral PresentationPresentation
Edgewise Therapeutics to present at Leerink Global Healthcare Conference
▲Oral PresentationSevasemtenFiledPresentation
Long-term MESA data presented at MDA 2026
Becker muscular dystrophysource ↗
◆Poster PresentationSevasemtenFiledPresentation
Long-term stabilization of function in Becker: Sevasemten prevented functional decline up to 3.5 years in MESA open-label extension
Becker muscular dystrophysource ↗
◆Poster PresentationSevasemtenFiledPresentation
Effects of sevasemten on LVEF and NT-proBNP in adults with Becker muscular dystrophy in CANYON
Becker muscular dystrophysource ↗
◆Poster PresentationPresentation
Female carriers of BMD and DMD mutations show elevated muscle injury proteins, and muscle loss progression is predicted by plasma ART3 concentration
Becker and Duchenne muscular dystrophysource ↗
◆Oral PresentationPresentation
Edgewise Lunch Forum: Elevating Becker Outcomes: Unlocking New Insights, Mobilizing Communities, and Redefining Care
Becker muscular dystrophysource ↗
◆Poster PresentationPresentation
Patient-focused drug development: Understanding the patient experience and meaningful treatment outcomes in Becker muscular dystrophy via interviews
Becker muscular dystrophysource ↗
◆Oral PresentationPresentation
Edgewise Therapeutics to present at Guggenheim Emerging Outlook: Biotech Summit 2026
◆Trial InitiationEDG-7500Trial
Phase 3 initiation planned for CIRRUS-HCM
hypertrophic cardiomyopathy (HCM)source ↗
▲Enrollment CompleteEDG-7500Trial
Completion of CIRRUS-HCM Phase 2 Parts B and C enrollment and dosing
hypertrophic cardiomyopathysource ↗
▲Safety Data UpdateEDG-7500Clinical Data
Favorable interim safety results from Part D of CIRRUS-HCM
hypertrophic cardiomyopathysource ↗
▲Enrollment MilestoneSevasemtenFiledTrial
99% of eligible participants enrolled in MESA open-label extension
Becker muscular dystrophysource ↗
◆Oral PresentationPresentation
Guggenheim 2nd Annual Healthcare Innovation Conference Fireside Chat
▲Trial InitiationEDG-15400Trial
Initiated Phase 1 healthy adult trial of EDG-15400
Heart Failure with preserved ejection fraction (HFpEF)source ↗
◆Poster PresentationSevasemtenFiledPresentation
Poster: LYNX Phase 2 trial results - positive effects on physical function defines dose and informs Phase 3 design
Duchenne muscular dystrophysource ↗
◆Oral PresentationSevasemtenFiledPresentation
Edgewise Symposium with KOLs discussing CANYON and MESA trial results
Becker muscular dystrophysource ↗
◆Timing GuidanceEDG-7500Presentation
Program update expected for CIRRUS-HCM trial
Hypertrophic cardiomyopathy (HCM)source ↗
▲Enrollment UpdateSevasemtenFiledTrial
MESA open-label extension trial continues to enroll nearly all eligible participants
Becker muscular dystrophysource ↗
▲Trial InitiationEDG-15400Trial
Initiated Phase 1 healthy adult trial of EDG-15400
Heart failure with preserved ejection fraction (HFpEF)source ↗
Past FDA Catalysts and PDUFA Decisions
How EWTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-31 | EDG-7500 | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C53 / 100
Pipeline Score
$1.0B
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.2x
rNPV / MCap
Top 13%
Small Cap(rank 86 of 658)
Percentile Rank
Edgewise Therapeutics, Inc. carries a moderate pipeline score (53/100), with $1.6B risk-adjusted pipeline value, led by EDG-7500 in Renal Impairments (Phase 1), across $69B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EDG-7500 Small moleculeNCT06347159 | Hypertrophic Cardiomyopathy | Phase 2 | ACTIVE NOT_RECRUITING | 79 | Dec 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every EWTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| EDG-7500 | symptomatic hypertrophic cardiomyopathy | Phase 2 | 2026-09-22 | generally safe and well tolerated and showing no clinically significant changes in left ventricular ejection fractionRead More | Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Donovan Joanne M.Officer (CMO) | Sell | -2,919 8,625 held | $43.41 | 08/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EWTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 11.7 % (20.6 %) | 630.52 M | 15.52 M |
EWTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EWTX ranks across every disease it competes in
Competitive Position is a premium feature
See how EWTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEWTX News
EWTX▲ +0.5%today
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
Edgewise Therapeutics has initiated the EQUINOX-HFpEF Phase 2 trial, dosing its first patient. This trial evaluates EDG-15400, an investigational drug for adults with symptomatic heart failure with preserved ejection fraction (HFpEF). The study aims to assess the drug's safety and efficacy in improving cardiac relaxation, addressing a significant unmet need in HFpEF treatment.
Read more →EWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics announced the granting of inducement stock options and RSU awards to three new non-executive employees as part of its 2024 Inducement Equity Incentive Plan. The stock options are priced at $40.60 per share, with a structured vesting schedule. This move is in compliance with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent.
Read more →EWTXEdgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
Edgewise Therapeutics announced the differentiated mechanism of action for its cardiac sarcomere modulator EDG-7500, which targets the Regulatory Light Chain to enhance cardiac relaxation while maintaining systolic function. The company will host a webcast to discuss these findings, which are supported by preclinical data and early clinical observations in patients with symptomatic hypertrophic cardiomyopathy. A peer-reviewed publication detailing the mechanism will also be released.
Read more →EWTXEdgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
Edgewise Therapeutics announced that its CIRRUS-HCM trial results will be presented at the ESC Congress 2026. The trial evaluated EDG-7500, a novel treatment for obstructive and nonobstructive hypertrophic cardiomyopathy. The presentation will take place on August 31, 2026, and aims to highlight the drug's safety and efficacy.
Read more →EWTXEdgewise Therapeutics Reports Second Quarter 2026 Financial Results
Edgewise Therapeutics reported positive results from its Phase 2 CIRRUS-HCM trial for EDG-7500, targeting hypertrophic cardiomyopathy. The company completed a significant sale of its sevasemten and muscular dystrophy business to Servier for up to $2.65 billion, enhancing its financial position. Despite a net loss of $57.3 million in Q2 2026, the company is focused on advancing its cardiovascular pipeline.
Read more →EWTX▼ -9.1%on this news
Servier finalise l'acquisition de l'activité dystrophie musculaire d'Edgewise Therapeutics
Servier has finalized the acquisition of Edgewise Therapeutics' muscular dystrophy business for up to $2.65 billion. This strategic move aims to bolster Servier's pipeline in rare neurological diseases, particularly with the experimental treatment sevasemten, which is in advanced stages of development. The acquisition is seen as a significant step towards Servier's ambition to provide innovative therapies for patients with unmet medical needs.
Read more →EWTX▼ -9.1%on this news
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
Servier has completed the acquisition of Edgewise Therapeutics' muscular dystrophy business for up to $2.65 billion. This acquisition includes an upfront payment of $1.55 billion and milestone payments. It aims to advance Servier's pipeline with the late-stage investigational treatment sevasemten, targeting Becker and Duchenne muscular dystrophies. The acquisition is seen as a strategic move to enhance Servier's capabilities in rare neurology.
Read more →EWTX▼ -9.1%on this news
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
Edgewise Therapeutics has completed the sale of sevasemten and its muscular dystrophy business to Servier for up to $2.65 billion. This transaction significantly enhances Edgewise's financial position and allows the company to focus on its cardiovascular pipeline, including EDG-7500 and EDG-15400. The upfront payment is expected to fully fund the development of EDG-7500 through potential approval.
Read more →EWTXEdgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
Edgewise Therapeutics announced positive top-line results from the 12-week Phase 2 CIRRUS-HCM trial of EDG-7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy (HCM). The trial demonstrated significant improvements in hemodynamic measures, biomarkers, and patient-reported outcomes. EDG-7500 was well tolerated, with no new safety signals identified, supporting its advancement to Phase 3 trials.
Read more →EWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics, Inc. ( Edgewise or the Company ), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel...
Edgewise Therapeutics, Inc. has announced the granting of inducement stock options for 74,000 shares to four new non-executive employees. This initiative is part of Edgewise's 2024 Inducement Equity Incentive Plan, which aims to attract talent in the company's pursuit of developing novel therapeutics for muscle diseases. The stock options have a set exercise price and vesting schedule, designed to incentivize long-term employment. These measures comply with Nasdaq Listing Rule 5635(c)(4), emphasizing the company's commitment to growth and employee retention.
Read more →EWTX▲ +17.9%on this newsshared move
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
Edgewise Therapeutics has entered into a definitive agreement to sell its muscular dystrophy business, including sevasemten, to Servier for up to $2.65 billion. The deal provides an upfront cash payment of $1.55 billion and potential additional milestone payments of up to $1.1 billion. This transaction will strengthen Edgewise's balance sheet and enable a concentrated focus on its cardiovascular pipeline, which includes key candidates like EDG-7500 and EDG-15400. The transaction is expected to close in Q3 2026, subject to customary conditions.
Read more →EWTX▲ +17.9%on this newsshared move
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that it has entered into a definitive ...
Edgewise Therapeutics has announced a definitive agreement to sell sevasemten and its muscular dystrophy business to Servier for up to $2.65 billion, including $1.55 billion upfront. This strategic move strengthens Edgewise's balance sheet and allows the company to concentrate on its cardiovascular pipeline, which includes products like EDG-7500 and EDG-15400. The upfront proceeds are expected to fully fund the development of EDG-7500 through potential approval, with additional revenue possible through milestone payments. The transaction is set to close in Q3 2026, pending regulatory approval.
Read more →EWTXEdgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
Edgewise Therapeutics will present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026. The presentation will be available via live webcast, allowing for broader access. The company is recognized for its development of novel therapeutics targeting muscular dystrophies and cardiac conditions.
Read more →EWTXEdgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
Edgewise Therapeutics reported their financial results for Q1 2026, highlighting advances in their clinical programs targeting muscular dystrophy and cardiovascular indications. Prominently, the company announced positive long-term data for sevasemten in Becker muscular dystrophy, showing sustained functional stability over 3.5 years. They also anticipate forthcoming results from the CIRRUS-HCM trial, aimed at evaluating a treatment for hypertrophic cardiomyopathy. The company is poised to report pivotal data from the GRAND CANYON trial in late 2026, which could support a marketing application for their treatments.
Read more →EWTXEdgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first...
Edgewise Therapeutics reported its financial results for Q1 2026, noting positive long-term data for sevasemten in Becker muscular dystrophy, demonstrating functional stabilization. The company is on track to present pivotal GRAND CANYON trial results in Q4 2026, which may support their first marketing application for Becker. Additionally, results from the CIRRUS-HCM trial are expected in Q2 2026, further refining their Phase 3 strategy. Despite these advancements, the company recorded an increased net loss attributed to higher R&D expenses.
Read more →EWTXEdgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 MDA Clinical and...
Edgewise Therapeutics presented positive long-term data from its MESA study, showing that sevasemten provides sustained functional stabilization in patients with Becker muscular dystrophy over 3.5 years. The study highlights that participants maintained function compared to predicted declines based on natural history. Sevasemten, a potential first treatment for Becker, exhibits a favorable safety profile and offers hope for this underserved population, with pivotal trial results anticipated by the end of 2026.
Read more →About Edgewise Therapeutics, Inc.
Headquarters1715 38TH ST, BOULDER, CO, 80301
BIOPHARMAWATCH ELITE PLUS
Trade the next EWTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime